Australia markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.11+0.17 (+0.68%)
As of 11:34AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.81B
Enterprise value 2.42B
Trailing P/E 26.36
Forward P/E 23.75
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.71
Price/book (mrq)5.94
Enterprise value/revenue 6.07
Enterprise value/EBITDA 18.60

Trading information

Stock price history

Beta (5Y monthly) 0.55
52-week change 319.27%
S&P500 52-week change 3-10.18%
52-week high 330.14
52-week low 315.83
50-day moving average 326.62
200-day moving average 324.76

Share statistics

Avg vol (3-month) 3556.07k
Avg vol (10-day) 3391.46k
Shares outstanding 5107.65M
Implied shares outstanding 6N/A
Float 888.63M
% held by insiders 111.13%
% held by institutions 181.81%
Shares short (14 Nov 2022) 416.34M
Short ratio (14 Nov 2022) 424.72
Short % of float (14 Nov 2022) 423.37%
Short % of shares outstanding (14 Nov 2022) 415.17%
Shares short (prior month 13 Oct 2022) 417.19M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 29.39%
Operating margin (ttm)31.89%

Management effectiveness

Return on assets (ttm)14.17%
Return on equity (ttm)23.06%

Income statement

Revenue (ttm)397.62M
Revenue per share (ttm)3.67
Quarterly revenue growth (yoy)5.80%
Gross profit (ttm)360.7M
EBITDA 127.69M
Net income avi to common (ttm)116.81M
Diluted EPS (ttm)1.00
Quarterly earnings growth (yoy)13.60%

Balance sheet

Total cash (mrq)396.26M
Total cash per share (mrq)3.68
Total debt (mrq)1.71M
Total debt/equity (mrq)0.36
Current ratio (mrq)8.52
Book value per share (mrq)4.40

Cash flow statement

Operating cash flow (ttm)136.36M
Levered free cash flow (ttm)116.63M